Drugs / TTP889
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00909298 | Jun 2009 → Jun 2010 | blood coagulation disease | vTv Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT00119457 | Jan 2005 → Apr 2006 | thrombotic disease, venous thromboembolism | vTv Therapeutics | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTP889 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00119457 ↗ |
| Action | Inhibit | “a small molecule that inhibits up to 90% of FIXa activity at therapeutic doses” PMID 18088349 ↗ Dec 2007 |
| Modality | Small molecule | “TTP889, a small molecule that inhibits up to 90% of FIXa activity at therapeutic doses” PMID 18088349 ↗ Dec 2007 |
| Route | Oral | “received oral TTP889 (300 mg once daily) or placebo” PMID 18088349 ↗ Dec 2007 |